Zinger Key Points
- The European Commission approved Bristol Myers' Breyanzi for relapsed or refractory follicular lymphoma after two or more prior treatments.
- In a Phase 2 trial, Breyanzi showed a 97.1% overall response rate and a 94.2% complete response rate in third-line plus treatment settings.
- Find out which stock just plummeted to the bottom of the new Benzinga Rankings. Updated daily—spot the biggest red flags before it’s too late.
On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co‘s BMY Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
The decision is based on global Phase 2 TRANSCEND FL study results.
Also Read: Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Among patients treated in the third-line plus setting, Breyanzi demonstrated a high overall response rate of 97.1% and a complete response (CR) rate of 94.2%, the study’s primary and key secondary endpoints, respectively.
Responses were rapid, durable, and demonstrated sustained efficacy, with a median time to first response of 0.95 months and 75.7% of patients still in response at 18 months.
Last March, the FDA granted accelerated approval to Breyanzi for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
In May, the FDA granted accelerated approval to Breyanzi for relapsed or refractory follicular lymphoma.
In November, Bristol Myers Squibb shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.
Price Action: BMY stock is down 1.92% at $59.13 at the last check Friday.
Read Next:
Image: Courtesy of Bristol Myers Squibb
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.